B. Nelson
Impact in
- Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Co-authors
- R. Mass (2 shared papers)Fairooz F. Kabbinavar (2 shared papers)William Novotny (2 shared papers)Taral Patel (1 shared paper)Michael McCleod (1 shared paper)John Hamm (1 shared paper)J. Randolph Hecht (1 shared paper)Joseph J. Schulz (1 shared paper)
- Journals
- Journal of Clinical Oncology (4 papers)Annals of Oncology (2 papers)European Urology (2 papers)European Journal of Cancer (1 paper)The Oncologist (1 paper)
- Partner nations
- United StatesFranceNetherlands
In The Last Decade
B. Nelson
12 papers receiving 1000 citations
B. Nelson's Hit Papers
Peers
Comparison fields: 5 of 69
- Oncology 795
- Hepatology 199
- Pulmonary and Respiratory Medicine 278
- Cancer Research 84
- Dermatology 46
Countries citing papers authored by B. Nelson
This map shows the geographic impact of B. Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Nelson more than expected).
Fields of papers citing papers by B. Nelson
This network shows the impact of papers produced by B. Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Nelson. The network helps show where B. Nelson may publish in the future.
Co-authors
The 25 scholars most cited alongside B. Nelson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial Hit paper breakdown → | 2005 | 709 |
| 2 | 2013 | 156 | |
| 3 | 2021 | 74 | |
| 4 | 2017 | 31 | |
| 5 | 2011 | 19 | |
| 6 | Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma | 2011 | 13 |
| 7 | 2004 | 11 | |
| 8 | 2021 | 5 | |
| 9 | 2019 | 5 | |
| 10 | 2011 | 4 | |
| 11 | 2016 | 3 | |
| 12 | 2011 | 2 |
About B. Nelson
B. Nelson is a scholar working on Oncology, Surgery, Molecular Biology, Organic Chemistry and Computational Theory and Mathematics, having authored 12 papers that have together received 1.0k indexed citations. Recurring topics across this work include Urinary and Genital Oncology Studies (5 papers), Melanoma and MAPK Pathways (5 papers), Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), Computational Drug Discovery Methods (3 papers), Colorectal Cancer Treatments and Studies (2 papers), Cancer Treatment and Pharmacology (2 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Oncology (795 citations), Hepatology (199 citations), Pulmonary and Respiratory Medicine (278 citations), Cancer Research (84 citations) and Dermatology (46 citations). B. Nelson has collaborated with scholars based in United States, France and Netherlands. Frequent co-authors include R. Mass, Fairooz F. Kabbinavar, William Novotny, Taral Patel, Michael McCleod, John Hamm, J. Randolph Hecht, Joseph J. Schulz, Caroline Robert and Thomas Powles. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Urology, European Journal of Cancer and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.